Latest News

African Institutions' Readiness to Conduct Phase 1 Bundibugyo Vaccine Trials

Database published of 45 African clinical trial units' readiness to conduct Phase 1 trials of Bundibugyo vaccines.

Moderna’s Bundibugyo ebolavirus vaccine candidate enters first human trial, backed by CEPI

The trial launch marks a major step forward in efforts to respond to the deadly Ebola outbreak in the Democratic Republic of the Congo (DRC).

Hilleman Laboratories to develop and produce CEPI-backed Bundibugyo ebolavirus vaccine doses for clinical trials

No vaccine is currently approved against the virus. The rVSV vaccine candidate could become an important tool for Bundibugyo outbreak control and response.